PMID- 14641143
OWN - NLM
STAT- MEDLINE
DCOM- 20040909
LR  - 20190922
IS  - 0141-9854 (Print)
IS  - 0141-9854 (Linking)
VI  - 25
IP  - 6
DP  - 2003 Dec
TI  - Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide 
      for patients with hematologic malignancies.
PG  - 383-91
AB  - We conducted a multi-center phase I/II trial of nonmyeloablative stem cell 
      transplantation for patients with hematologic malignancies. The aim of this trial 
      was to assess the safety and feasibility of this treatment modality for older or 
      younger patients with significant organ dysfunction, who could not be treated 
      with conventional high dose chemoradiotherapy. Twelve patients were treated with 
      a conditioning regimen consisting of fludarabine and cyclophosphamide, followed 
      by peripheral blood stem cell transplantation from human leukocyte antigen (HLA) 
      identical siblings. Nonhematologic toxicities were mild. Median time to absolute 
      neutrophils above 0.5 x 10(9)/l, 1.0 x 10(9)/l and platelets above 50 x 10(9)/l 
      were 8, 10 and 12 days, respectively. Donor dominant hematopoiesis was achieved 
      in all patients, with or without donor leukocyte infusion. The cumulative 
      incidence of acute and chronic graft-versus-host disease (GVHD) was 75 and 56%, 
      respectively. Only one patient experienced early death within 100 days, caused by 
      acute GVHD complicated by fungal infection. All patients except one achieved 
      complete remission. With a median follow-up of 330 days, expected 
      progression-free survival is 75%. Overall survival is 76%. Our study confirms 
      that nonmyeloablative stem cell transplantation with cyclophosphamide and 
      fludarabine conditioning is a safe and promising treatment for elderly patients 
      with hematologic malignancies. A further study in large-scale setting is 
      warranted.
FAU - Nakajima, H
AU  - Nakajima H
AD  - Division of Hematology/Medical Oncology, Tokai University School of Medicine, 
      Boseidai, Isehara, Japan.
FAU - Oki, M
AU  - Oki M
FAU - Kishi, K
AU  - Kishi K
FAU - Ueyama, Jun-Ichi
AU  - Ueyama J
FAU - Miyakoshi, S
AU  - Miyakoshi S
FAU - Hatsumi, N
AU  - Hatsumi N
FAU - Sakura, T
AU  - Sakura T
FAU - Miyawaki, S
AU  - Miyawaki S
FAU - Yokota, A
AU  - Yokota A
FAU - Fujisawa, S
AU  - Fujisawa S
FAU - Mori, S
AU  - Mori S
FAU - Tanaka, Y
AU  - Tanaka Y
FAU - Sakamaki, H
AU  - Sakamaki H
CN  - Kanto Study Group for Cell Therapy
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Clin Lab Haematol
JT  - Clinical and laboratory haematology
JID - 7907061
RN  - 0 (Benzamides)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - FA2DM6879K (Vidarabine)
RN  - P2K93U8740 (fludarabine)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Benzamides
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/administration & dosage
MH  - Disease-Free Survival
MH  - Feasibility Studies
MH  - Female
MH  - Graft Survival
MH  - Graft vs Host Disease/epidemiology/etiology
MH  - Hematologic Neoplasms/drug therapy/mortality/*therapy
MH  - Humans
MH  - Imatinib Mesylate
MH  - Incidence
MH  - Leukocyte Transfusion
MH  - Life Tables
MH  - Male
MH  - Middle Aged
MH  - Neoplasm, Residual
MH  - *Peripheral Blood Stem Cell Transplantation/adverse effects
MH  - Piperazines/administration & dosage
MH  - Pyrimidines/administration & dosage
MH  - Remission Induction
MH  - Survival Analysis
MH  - Transplantation Chimera
MH  - Transplantation Conditioning
MH  - Treatment Outcome
MH  - Vidarabine/administration & dosage/*analogs & derivatives
EDAT- 2003/12/03 05:00
MHDA- 2004/09/10 05:00
CRDT- 2003/12/03 05:00
PHST- 2003/12/03 05:00 [pubmed]
PHST- 2004/09/10 05:00 [medline]
PHST- 2003/12/03 05:00 [entrez]
AID - 550 [pii]
AID - 10.1046/j.0141-9854.2003.00550.x [doi]
PST - ppublish
SO  - Clin Lab Haematol. 2003 Dec;25(6):383-91. doi: 10.1046/j.0141-9854.2003.00550.x.